Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro. (Q54125905)

25 May 2018

title

Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro. (English)

1 reference

25 May 2018

author name string

Evis Havari

1

1 reference

25 May 2018

Michael J Turner

2

1 reference

25 May 2018

Juanita Campos-Rivera

3

1 reference

25 May 2018

Srinivas Shankara

4

1 reference

25 May 2018

Tri-Hung Nguyen

5

1 reference

25 May 2018

Bruce Roberts

6

1 reference

25 May 2018

William Siders

7

1 reference

25 May 2018

Johanne M Kaplan

8

1 reference

25 May 2018

publication date

1 January 2014

1 reference

25 May 2018

published in

Immunology

1 reference

25 May 2018

volume

141

1 reference

25 May 2018

issue

1

1 reference

25 May 2018

page(s)

123-131

1 reference

25 May 2018

Campath-1H monoclonal antibody therapy

cites work

1 reference

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis

21 January 2018

1 reference

Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein

21 January 2018

1 reference

Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis

21 January 2018

1 reference

Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy

21 January 2018

1 reference

Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation

21 January 2018

1 reference

Characterization of the 4C8 antigen involved in transendothelial migration of CD26(hi) T cells after tight adhesion to human umbilical vein endothelial cell monolayers

21 January 2018

1 reference

CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.

21 January 2018

1 reference

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.

21 January 2018

1 reference

Alemtuzumab induction of intracellular signaling and apoptosis in malignant B lymphocytes

21 January 2018

1 reference

Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells

21 January 2018

1 reference

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

21 January 2018

1 reference

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

21 January 2018

1 reference

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

21 January 2018

1 reference

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

21 January 2018

1 reference

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis

21 January 2018

1 reference

CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H.

21 January 2018

1 reference

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

21 January 2018

1 reference

Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance

21 January 2018

1 reference

Control of regulatory T cell development by the transcription factor Foxp3

21 January 2018

1 reference

The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3

21 January 2018

1 reference

Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse

21 January 2018

1 reference

FOXP3 acts as a rheostat of the immune response

21 January 2018

1 reference

21 January 2018

FOXP3: of mice and men.

1 reference

Multiple sclerosis and regulatory T cells

21 January 2018

1 reference

T regulatory cells are markers of disease activity in multiple sclerosis patients

21 January 2018

1 reference

CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis

21 January 2018

1 reference

Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis

21 January 2018

1 reference

The role of regulatory T cells in multiple sclerosis

21 January 2018

1 reference

Natural regulatory T cells: mechanisms of suppression

21 January 2018

1 reference

Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target

21 January 2018

1 reference

Regulation of CD4+CD25+ regulatory T cell activity: it takes (IL-)two to tango

21 January 2018

1 reference

A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions

21 January 2018

1 reference

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity

21 January 2018

1 reference

T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.

21 January 2018

1 reference

Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells

21 January 2018

1 reference

Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function.

21 January 2018

1 reference

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses

21 January 2018

1 reference

Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state

21 January 2018

1 reference

CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production

21 January 2018

1 reference

CD25+ CD4+ T cells compete with naive CD4+ T cells for IL-2 and exploit it for the induction of IL-10 production.

21 January 2018

1 reference

CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells

21 January 2018

1 reference

Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system.

21 January 2018

1 reference

Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases

21 January 2018

1 reference

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases

21 January 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3893855

Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans

2 November 2018

1 reference

12 December 2020

Altered frequency of T regulatory cells is associated with disability status in relapsing-remitting multiple sclerosis patients

1 reference

12 December 2020

Effect of Campath-1H antibody on human hematopoietic progenitors in vitro

1 reference

12 December 2020

In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma

1 reference

12 December 2020

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen

1 reference

12 December 2020

Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H

1 reference

12 December 2020

The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H

1 reference

12 December 2020

Competition for cytokines: T(reg) cells take all

1 reference

12 December 2020

Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes

1 reference

12 December 2020

ANTI-CD3 therapy expands the numbers of CD4+ and CD8+ Treg cells and induces sustained amelioration of collagen-induced arthritis

1 reference

12 December 2020

The CAMPATH-1 antigen (CDw52)

1 reference

12 December 2020

Identifiers

DOI

10.1111/IMM.12178

1 reference

25 May 2018

PMC publication ID

3893855

0 references

1 reference

25 May 2018